UnitedHealth Expands Coverage for Guardant Health’s Shield Blood Test
Event summary
- UnitedHealth Group now covers Guardant Health’s Shield blood test for colorectal cancer screening for eligible members aged 45+.
- Shield is the first and only FDA-approved blood test for primary colorectal cancer screening in average-risk adults.
- Approximately 40 million Americans covered by UHG plans, including employer, individual, Medicare Advantage, and supplemental Medicare beneficiaries, now have access to Shield.
- Shield is included in both American Cancer Society (ACS) and National Comprehensive Cancer Network (NCCN) guidelines.
The big picture
UnitedHealth’s coverage of Shield marks a significant milestone in making colorectal cancer screening more accessible, addressing the rising incidence of CRC in adults under 65. This strategic move aligns with broader industry trends toward non-invasive, blood-based screening options that overcome barriers associated with traditional methods. Guardant Health’s inclusion in ACS and NCCN guidelines further solidifies Shield’s position as a critical tool in preventive care.
What we're watching
- Market Adoption
- How quickly other major insurers will follow UnitedHealth in covering Shield, expanding access to colorectal cancer screening.
- Clinical Impact
- Whether the real-world evidence and clinical performance of Shield will drive broader acceptance among healthcare providers.
- Competitive Dynamics
- The pace at which Guardant Health can scale its commercial expansion amid rising colorectal cancer rates in younger populations.
Related topics